Take on asthma from another angle1
SPIRIVA RESPIMAT is the first and only anticholinergic that works differently to address bronchoconstriction in patients.1
Demonstrated safety profile1
Multiple clinical trials with almost 4,500 asthma patients confirmed the demonstrated safety profile of SPIRIVA RESPIMAT.1
Improves lung function1*
SPIRIVA RESPIMAT improves lung function (peak and trough FEV1) in asthma patients on an ICS or ICS/LABA and reduces the rate of exacerbations in adults.1†
In the treatment of asthma, the maximum benefits in lung function may take up to 4 to 8 weeks of dosing.
Asthma-specific dosing in a steroid-free mist1
SPIRIVA RESPIMAT offers asthma-specific dosing—1.25 mcg/puff (2 puffs, once daily)—in a steroid-free mist1
*For peak forced expiratory volume in 1 second (FEV1, 0–3hr) and trough FEV1
†An asthma exacerbation was defined as an episode of progressive increase in ≥1 asthma symptom(s) (like shortness of breath, cough, wheezing, chest tightness, or some combination of these symptoms) or a decrease of a patient’s best morning peak expiratory flow (PEF) of 30% from a patient’s mean morning PEF for ≥2 consecutive days that required the initiation or increase in treatment with systemic steroids for ≥3 days.
Eligible patients with asthma
may pay as little as $0*
*Eligible commercially insured patients or patient guardians who are 18 years or older may pay as little as $0/month with a maximum savings up to $100/monthly prescription. Card valid for 12 fills per year with benefits not to exceed program expiration on 12/31/2019. If you live in Massachusetts, card expires on the earlier of December 31, 2019, or date AB rated generic equivalent is available. Other state restrictions may apply. One card per patient, not transferable, and cannot be combined with any other offer. Card not accepted in Veteran’s Affairs pharmacies. Program not health insurance. You must present this card to the pharmacist with your Spiriva Respimat prescription to participate. Only valid for commercially insured patients in the 50 United States, territories, DC, and Puerto Rico. Offer not valid for patients without commercial coverage or patients whose prescriptions for Spiriva Respimat are eligible to be reimbursed, in whole or in part, by any governmental program such as Medicaid, Medicare or any state patient or pharmaceutical assistance program and where prohibited by law. Offer may change at any time, without notice.